{"id":"https://openalex.org/W4379282927","doi":"https://doi.org/10.1200/jco.2023.41.16_suppl.e17598","title":"Real-world outcomes of first-line maintenance with niraparib or bevacizumab in advanced ovarian cancer.","display_name":"Real-world outcomes of first-line maintenance with niraparib or bevacizumab in advanced ovarian cancer.","publication_year":2023,"publication_date":"2023-06-01","ids":{"openalex":"https://openalex.org/W4379282927","doi":"https://doi.org/10.1200/jco.2023.41.16_suppl.e17598"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2023.41.16_suppl.e17598","doi":"https://doi.org/10.1200/jco.2023.41.16_suppl.e17598","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2023.41.16_suppl.e17598","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5112209207","display_name":"Anupama Vasudevan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210100046","display_name":"Integra (United States)","ror":"https://ror.org/00ynqbp15","country_code":"US","type":"company","lineage":["https://openalex.org/I4210100046"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Anupama Vasudevan","raw_affiliation_strings":["Precision Q, Integra Connect, West Palm Beach, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Precision Q, Integra Connect, West Palm Beach, FL","institution_ids":["https://openalex.org/I4210100046"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083630595","display_name":"Sandy English","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210100046","display_name":"Integra (United States)","ror":"https://ror.org/00ynqbp15","country_code":"US","type":"company","lineage":["https://openalex.org/I4210100046"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sandy English","raw_affiliation_strings":["Precision Q, Integra Connect, West Palm Beach, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Precision Q, Integra Connect, West Palm Beach, FL","institution_ids":["https://openalex.org/I4210100046"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082874612","display_name":"Mike Gart","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210100046","display_name":"Integra (United States)","ror":"https://ror.org/00ynqbp15","country_code":"US","type":"company","lineage":["https://openalex.org/I4210100046"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mike Gart","raw_affiliation_strings":["Precision Q, Integra Connect, West Palm Beach, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Precision Q, Integra Connect, West Palm Beach, FL","institution_ids":["https://openalex.org/I4210100046"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066876363","display_name":"Taofikat Oladipo","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210100046","display_name":"Integra (United States)","ror":"https://ror.org/00ynqbp15","country_code":"US","type":"company","lineage":["https://openalex.org/I4210100046"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Taofikat Oladipo","raw_affiliation_strings":["Precision Q, Integra Connect, West Palm Beach, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Precision Q, Integra Connect, West Palm Beach, FL","institution_ids":["https://openalex.org/I4210100046"]}]},{"author_position":"middle","author":{"id":null,"display_name":"John Hartman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"John Hartman","raw_affiliation_strings":["GSK, Philadelphia, PA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GSK, Philadelphia, PA","institution_ids":["https://openalex.org/I4210114143"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109611137","display_name":"Laura L. Iadeluca","orcid":"https://orcid.org/0000-0002-2379-6094","observed_orcids":["https://orcid.org/0000-0002-2379-6094"]},"institutions":[{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Laura L. Iadeluca","raw_affiliation_strings":["GSK, Philadelphia, PA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GSK, Philadelphia, PA","institution_ids":["https://openalex.org/I4210114143"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5027795459","display_name":"Fred J. Kudrik","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210106157","display_name":"South Carolina Oncology Associates","ror":"https://ror.org/01qh4s373","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210106157"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Fred J. Kudrik","raw_affiliation_strings":["South Carolina Oncology Associates, West Columbia, SC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"South Carolina Oncology Associates, West Columbia, SC","institution_ids":["https://openalex.org/I4210106157"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":3,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"41","issue":"16_suppl","first_page":"e17598","last_page":"e17598"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":0.8769999742507935,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":0.8769999742507935,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10550","display_name":"Ovarian cancer diagnosis and treatment","score":0.12210000306367874,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10769","display_name":"BRCA gene mutations in cancer","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/1311","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/advanced-ovarian-cancer","display_name":"advanced ovarian cancer","score":0.9760000109672546},{"id":"https://openalex.org/keywords/first-line-maintenance-therapy","display_name":"first-line maintenance therapy","score":0.9620000123977661},{"id":"https://openalex.org/keywords/niraparib","display_name":"niraparib","score":0.9950000047683716},{"id":"https://openalex.org/keywords/bevacizumab","display_name":"bevacizumab","score":1.0},{"id":"https://openalex.org/keywords/time-to-next-treatment","display_name":"time to next treatment","score":0.6930000185966492},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.800000011920929},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.9419999718666077},{"id":"https://openalex.org/keywords/homologous-recombination-deficiency","display_name":"homologous recombination deficiency","score":0.9169999957084656},{"id":"https://openalex.org/keywords/parp-inhibitors","display_name":"PARP inhibitors","score":0.7540000081062317},{"id":"https://openalex.org/keywords/real-world-outcomes","display_name":"real-world outcomes","score":0.7250000238418579},{"id":"https://openalex.org/keywords/induction-chemotherapy","display_name":"induction chemotherapy","score":0.5490000247955322},{"id":"https://openalex.org/keywords/brca-status","display_name":"BRCA mutation status","score":0.6919999718666077},{"id":"https://openalex.org/keywords/hrd-testing","display_name":"HRD testing","score":0.5460000038146973},{"id":"https://openalex.org/keywords/ecog-performance-status","display_name":"ECOG performance status","score":0.6850000023841858}],"concepts":[{"id":"https://openalex.org/C2777802072","wikidata":"https://www.wikidata.org/wiki/Q413299","display_name":"Bevacizumab","level":3,"score":0.96113121509552},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9387251138687134},{"id":"https://openalex.org/C2780427987","wikidata":"https://www.wikidata.org/wiki/Q172341","display_name":"Ovarian cancer","level":3,"score":0.6875855326652527},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.6768093109130859},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6039704084396362},{"id":"https://openalex.org/C2778283404","wikidata":"https://www.wikidata.org/wiki/Q6736822","display_name":"Maintenance therapy","level":3,"score":0.5503189563751221},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.5325034856796265},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3960517346858978},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.3444083631038666}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2023.41.16_suppl.e17598","doi":"https://doi.org/10.1200/jco.2023.41.16_suppl.e17598","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2023.41.16_suppl.e17598","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9940000176429749,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4281698295","https://openalex.org/W7127613404","https://openalex.org/W4379282058","https://openalex.org/W4404190602","https://openalex.org/W4414649593","https://openalex.org/W4400316939","https://openalex.org/W4297769733","https://openalex.org/W4403250866","https://openalex.org/W3202036125","https://openalex.org/W4411858265"],"abstract_inverted_index":{"e17598":[0],"Background:":[1],"Niraparib":[2],"and":[3,68,72,113,152,189,201,229,247,280,309],"bevacizumab":[4,52,62,157,199,220,265],"are":[5,302],"the":[6,27,33,43,76,84,90,128,167,241,292,316],"only":[7,274],"FDA-approved":[8],"first-line":[9,159,195],"maintenance":[10,87,262],"(1LM)":[11],"therapies":[12],"for":[13,110,117,236,256,276,288,307],"advanced":[14],"ovarian":[15],"cancer":[16,138,177],"(AOC)":[17],"without":[18],"a":[19,107,222,230,286],"biomarker":[20],"requirement.":[21],"However,":[22],"little":[23],"information":[24],"exists":[25],"regarding":[26],"effectiveness":[28],"of":[29,79,86,187,225,234,278,282],"these":[30,118,308],"treatments":[31],"in":[32,291,315],"real":[34,293],"world.":[35,294],"Methods:":[36],"We":[37],"identified":[38],"89":[39],"AOC":[40,259],"patients":[41,123,162,209,237,260],"from":[42],"US-based":[44],"deidentified":[45],"Integra":[46],"PrecisionQ":[47],"database":[48],"who":[49,124,163],"received":[50,125,154,164,191],"1LM":[51,126,165],"(n=31)":[53],"or":[54,101,264],"niraparib":[55,203,263],"(n=58)":[56],"following":[57,266],"induction":[58],"chemotherapy":[59,192],"(CT)":[60],"\u00b1":[61],"initiated":[63],"between":[64],"July":[65],"1,":[66],"2019,":[67],"March":[69,80],"31,":[70,81],"2021,":[71],"followed":[73],"them":[74],"until":[75],"data":[77,255],"cut-off":[78],"2022.":[82],"Using":[83],"start":[85],"therapy":[88],"as":[89,106,158,194],"index":[91,140,179],"date,":[92,141,180],"we":[93],"examined":[94],"patient":[95,300],"characteristics,":[96],"time":[97],"to":[98,313],"next":[99],"treatment":[100,119,311],"death":[102],"(TTNT;":[103],"often":[104],"used":[105],"real-world":[108,253],"proxy":[109],"progression-free":[111],"survival),":[112],"overall":[114],"survival":[115,306],"(OS)":[116],"groups.":[120],"Results:":[121],"For":[122,161],"bevacizumab,":[127],"median":[129,168,223],"age":[130,169],"was":[131,170],"69":[132],"years,":[133,172],"65%":[134],"had":[135,143,174,182,210,221],"Stage":[136,175],"III":[137,176],"at":[139,178],"84%":[142],"Eastern":[144],"Cooperative":[145],"Oncology":[146],"Group":[147],"(ECOG)":[148],"performance":[149,185],"status":[150,186],"0\u20131,":[151,188],"87%":[153],"CT":[155,267],"+":[156],"therapy.":[160,196],"niraparib,":[166,240],"68.5":[171],"66%":[173],"88%":[181],"an":[183],"ECOG":[184],"79%":[190],"alone":[193],"Only":[197],"1":[198],"(BRCAm)":[200],"11":[202],"(4":[204],"BRCAm,":[205],"7":[206],"BRCAwt":[207],"HRd)":[208],"known":[211],"homologous":[212],"recombination":[213],"deficiency":[214],"(HRd)-positive":[215],"tumors.":[216],"Patients":[217],"treated":[218,238],"with":[219,239,304],"TTNT":[224],"4.5":[226],"months":[227],"(mo)":[228],"12-month":[231],"OS":[232],"mark":[233],"83.6%;":[235],"corresponding":[242],"values":[243],"were":[244,273],"9.9":[245],"mo":[246],"96.3%.":[248],"Conclusions:":[249],"Our":[250],"study":[251],"provides":[252],"outcomes":[254],"newly":[257],"diagnosed":[258],"receiving":[261],"+/-":[268],"bevacizumab.":[269],"HRd":[270],"testing":[271,290],"results":[272],"available":[275],"19%":[277],"bevacizumab-":[279],"40%":[281],"niraparib-treated":[283],"patients,":[284],"highlighting":[285],"need":[287],"greater":[289],"Future":[295],"studies":[296],"should":[297],"examine":[298],"which":[299],"characteristics":[301],"associated":[303],"long-term":[305],"other":[310],"options":[312],"aid":[314],"decision-making":[317],"process.":[318],"Funding:":[319],"GSK215281.":[320],"[Table:":[321],"see":[322],"text]":[323]},"counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":2}],"updated_date":"2026-10-12T09:40:04.860316","created_date":"2023-06-05T00:00:00"}